研究活動情報

• Erythropoietin Resistance and Outcomes According to SGLT2 Inhibitor Use in Anemic Patients With Heart Failure
  TOSHIFUMI TAMURA; TOSHIYUKI NAGAI; MOTOKI NAKAO; SHU TAHARA; YOSHIFUMI MIZUGUCHI; TARO KOYA; ATSUSHI TADA; FUSAKO GEORGE; ISAO YOKOTA; YOSHIYA KATO; SHOGO IMAGAWA; YUSUKE TOKUDA; MASASHIGE TAKAHASHI; JUNICHI MATSUMOTO; KO MOTOI; YUTAKA WAKAMATSU; MASAHARU MACHIDA; TAKAHIKO SAITO; TOSHIHISA ANZAI
  Journal of Cardiac Failure, 2026年08月
  研究論文（学術雑誌）
• Prognostic Value of Mid-Range QRS Duration in Patients With Heart Failure With Reduced Ejection Fraction.
  Shota Saito; Taro Temma; Toshiyuki Nagai; Motoki Nakao; Isao Yokota; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Yuki Takahashi; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Junichi Matsumoto; Masashige Takahashi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihiro Shimizu; Toshihisa Anzai
  Circulation journal : official journal of the Japanese Circulation Society, 2026年04月25日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Prolonged QRS is an established marker of adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the prognostic significance of modest QRS prolongation (120-149 ms; mid-range QRS) remains unclear, especially in patients without cardiac implantable electronic devices (CIEDs). This study assessed the natural prognosis associated with mid-range QRS compared with narrow QRS (<120 ms) in a recent Asian cohort of patients with HFrEF. METHODS AND RESULTS: We analyzed patients with HFrEF from the Epidemiological Multicenter Study for Tailored Treatment in Heart Failure (ELMSTAT-HF; January 2020-October 2023). QRS was measured from 12-lead electrocardiograms. Patients with wide QRS (≥150 ms) or CIEDs were excluded. The primary outcome was a composite of all-cause mortality and heart failure hospitalizations. Multivariable Cox models adjusted for the MAGGIC risk score and log-transformed N-terminal pro B-type natriuretic peptide were used. Among 415 patients, 328 had narrow QRS and 87 had mid-range QRS. Over a median follow-up of 547 days, the primary outcome occurred more frequently in the mid-range QRS group (34.5% vs. 12.5%; P<0.001). Mid-range QRS remained independently associated with adverse outcomes (hazard ratio 3.12; 95% confidence interval 1.91-5.11), consistent across non-left bundle branch block (LBBB) and LBBB subgroups. CONCLUSIONS: Mid-range QRS is an independent predictor of adverse outcomes in HFrEF, even in the absence of LBBB.
• Clinical Phenotyping and Treatment Response in Patients With Chronic Heart Failure
  Daishiro Tatsuta; Motoki Nakao; Toshiyuki Nagai; Yoshifumi Mizuguchi; Isao Yokota; Taro Koya; Atsushi Tada; Suguru Ishizaka; Fusako George; Yoshiya Kato; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Masaharu Machida; Hiroshi Okamoto; Takahiko Saito; Toshihisa Anzai
  JACC: Advances, 4, 8, 101972, 101972, Elsevier BV, 2025年08月
  研究論文（学術雑誌）
• Prognostic Value of Reticulocyte Production Ability in Patients with Chronic Heart Failure.
  Motoki Nakao; Toshiyuki Nagai; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
  The Canadian journal of cardiology, 2025年02月07日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Anemia is frequently observed and associated with mortality in patients with heart failure (HF). Although the quality of erythropoiesis is an intrinsic aspect of anemia's pathophysiology, its prognostic value in HF patients is unclear. METHODS: Between January 2020 and October 2023, 1,328 symptomatic patients with chronic HF from a multicenter registry were prospectively examined. The reticulocyte production ability was evaluated by calculating the reticulocyte production index (RPI) using reticulocyte counts and serum hematocrit level. Patients were divided into four groups based on the presence or absence of anemia and the median RPI. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: During a median follow-up of 551 (interquartile range 321-712) days, the primary outcome occurred in 219 patients. The incidence of the primary outcome was high among patients in the anemia and higher RPI group (≥ 0.978) (P <0.001). Higher RPI was independently associated with a higher risk of the primary outcome, even after adjusting for prognostic covariates (adjusted HR 1.37; 95% CI 1.05-1.78). Erythrocyte counts were significantly higher in patients with higher RPI in the groups without anemia (P <0.001); however, no significant differences were observed between the groups with anemia (P = 0.923). Serum iron levels and transferrin saturation did not significantly differ between the RPI groups with or without anemia. CONCLUSIONS: Higher RPI, which may reflect impaired maturation or a shortened lifespan of erythrocytes, was associated with worse clinical outcomes in HF patients irrespective of iron status.
• Differential impacts of self-care behavior on clinical outcomes in patients with and without recent heart failure hospitalization
  Taro Koya; Toshiyuki Nagai; Atsushi Tada; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Fusako George; Shogo Imagawa; Yusuke Tokuda; Yoshiya Kato; Masashige Takahashi; Hiroto Sakai; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Hiroshi Okamoto; Toshihisa Anzai
  International Journal of Cardiology, 132452, 132452, Elsevier BV, 2024年08月
  研究論文（学術雑誌）